RNA polymerase II transcription is required for human papillomavirus type 16 E7-and hydroxyurea-induced centriole overduplication

被引:16
作者
Duensing, A.
Liu, Y.
Spardy, N.
Bartoli, K.
Tseng, M.
Kwon, J-A
Teng, X.
Duensing, S.
机构
[1] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Sch Med, Biochem & Mol Genet Grad Program, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA
关键词
HPV-16; E7; hydroxyurea; centrioles; RNA polymerase II; cyclin A;
D O I
10.1038/sj.onc.1209782
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aberrant centrosome numbers are detected in virtually all human cancers where they can contribute to chromosomal instability by promoting mitotic spindle abnormalities. Despite their widespread occurrence, the molecular mechanisms that underlie centrosome amplification are only beginning to emerge. Here, we present evidence for a novel regulatory circuit involved in centrosome overduplication that centers on RNA polymerase II (pol II). We found that human papillomavirus type 16 E7(HPV-16 E7)- and hydroxyurea (HU)-induced centriole overduplication are abrogated by alpha-amanitin, a potent and specific RNA pol II inhibitor. In contrast, normal centriole duplication proceeded undisturbed in alpha-amanitin-treated cells. Centriole overduplication was significantly reduced by siRNA-mediated knock down of CREB-binding protein (CBP), a transcriptional co-activator. We identifi ed cyclin A2 as a key transcriptional target of RNA pol II during HU-induced centriole overduplication. Collectively, our results show that ongoing RNA pol II transcription is required for centriole overduplication whereas it may be dispensable for normal centriole duplication. Given that many chemotherapeutic agents function through inhibition of transcription, our results may help to develop strategies to target centrosome-mediated chromosomal instability for cancer therapy and prevention.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 50 条
[31]   To cycle or not to cycle: A critical decision in cancer [J].
Malumbres, M ;
Barbacid, M .
NATURE REVIEWS CANCER, 2001, 1 (03) :222-231
[32]   p21cip-1/waf-1 deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells [J].
Mantel, C ;
Braun, SE ;
Reid, S ;
Henegariu, O ;
Liu, L ;
Hangoc, G ;
Broxmeyer, HE .
BLOOD, 1999, 93 (04) :1390-1398
[33]   Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E [J].
Martin, LG ;
Demers, GW ;
Galloway, DA .
JOURNAL OF VIROLOGY, 1998, 72 (02) :975-985
[34]   Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells [J].
Matsumoto, Y ;
Hayashi, K ;
Nishida, E .
CURRENT BIOLOGY, 1999, 9 (08) :429-432
[35]   p16INK4a prevents centrosome dysfunction and genomic instability in primary cells [J].
McDermott, KM ;
Zhang, JM ;
Holst, CR ;
Kozakiewicz, BK ;
Singla, V ;
Tlsty, TD .
PLOS BIOLOGY, 2006, 4 (03) :350-365
[36]   Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A [J].
Meraldi, P ;
Lukas, J ;
Fry, AM ;
Bartek, J ;
Nigg, EA .
NATURE CELL BIOLOGY, 1999, 1 (02) :88-93
[37]   Control of DNA replication and chromosome ploidy by geminin and cyclin A [J].
Mihaylov, IS ;
Kondo, T ;
Jones, L ;
Ryzhikov, S ;
Tanaka, J ;
Zheng, JY ;
Higa, LA ;
Minamino, N ;
Cooley, L ;
Zhang, H .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (06) :1868-1880
[38]   Biological activities and molecular targets of the human papillomavirus E7 oncoprotein [J].
Münger, K ;
Basile, JR ;
Duensing, S ;
Eichten, A ;
Gonzalez, SL ;
Grace, M ;
Zacny, VL .
ONCOGENE, 2001, 20 (54) :7888-7898
[39]   Human papillomavirus immortalization and transformation functions [J].
Münger, K ;
Howley, PM .
VIRUS RESEARCH, 2002, 89 (02) :213-228
[40]   Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression [J].
Mussman, JG ;
Horn, HF ;
Carroll, PE ;
Okuda, M ;
Tarapore, P ;
Donehower, LA ;
Fukasawa, K .
ONCOGENE, 2000, 19 (13) :1635-1646